Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1504396
This article is part of the Research Topic Antimicrobial Resistance: Causes, Mechanisms and Mitigation Strategies for Gut Dysbiosis View all 3 articles

Effects of multi-resistant bacteria and multi-antibiotic combination on intestinal microbiota in mice

Provisionally accepted
Jing Ma Jing Ma 1Zheng Gong Zheng Gong 1Meiling Kang Meiling Kang 1Zhongjing Tian Zhongjing Tian 1Liping You Liping You 2Chengshi Ding Chengshi Ding 1,3*
  • 1 College of Life Sciences, Zaozhuang University, Zaozhuang, Shandong, China
  • 2 Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China
  • 3 Zaozhuang University, Zaozhuang, China

The final, formatted version of the article will be published soon.

    Multidrug-resistant bacteria is a clinical and an epidemiological challenge. However, the effects of multi-resistant bacteria and multi-antibiotic combination on gut microbiota are unclear.Here, effects of multi-resistant bacteria and multi-antibiotic combination on intestinal microbiota in mice were observed by high-throughput sequencing. Resistant Escherichia coli (RP4) and 0.5 mg/L, 1 mg/L, 2 mg/L antibiotic (Amp, Km, and Tet multi-antibiotic combination) could decrease the number of specific OTUs from 223 in NS control group to 178 in antibiotic resistant bacteria group and 34 in antibiotic group, and antibiotics are the biggest influencing factor. Multi-resistant bacteria and multi-antibiotic combination could affect the function of intestinal microbiota, and the effect of multi-resistant bacteria was similar to multi-antibiotic combination. Small intestine is the main colonization sites of antibiotic resistant bacteria, and Proteobacteria and Bacteroidetes are the main antibiotic resistance acquired bacteria by TEM and agarose plate screening culture.

    Keywords: multidrug-resistant Escherichia coli, multi-antibiotic combination, intestinal microbiota, high-throughput sequencing, antibiotics

    Received: 30 Sep 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 Ma, Gong, Kang, Tian, You and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Chengshi Ding, Zaozhuang University, Zaozhuang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.